You are viewing the site in preview mode

Skip to main content
Fig. 1 | Cancer Communications

Fig. 1

From: The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

Fig. 1

Graphical representation of the study design of this ACTIVE (CTONG1706) study. NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor, ECOG PS Eastern Cooperative Oncology Group performance status, OS overall survival, ORR objective response rate, DCR disease control rate, TTPD time to progressive disease, QoL quality of life, PD progression disease

Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us